Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antidepressants and suicidality. Risk-benefit analysis].

U Hegerl1

  • 1Abteilung für Klinische Neurophysiologie, Psychiatrische Klinik der Ludwig-Maximilians-Universität, Nussbaumstrasse 7, 80336 München. ulrich.hegerl@psy.med.uni-muenchen.de

Der Nervenarzt
|June 23, 2006
PubMed
Summary

Antidepressants like SSRIs may increase suicidal thoughts in children and adolescents, though completed suicides weren't observed. For adults, these drugs remain vital for reducing suicide risk and treating depression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Telemedicine during the COVID-19 pandemic in Germany: Results from three nationally representative surveys on use, attitudes and barriers among adults affected by depression.

Internet interventions·2023
Same author

[Workload in emergency departments : A Problem for personnel and patients?]

Der Anaesthesist·2019
Same author

Reflections on causes of suicidal behaviour.

Epidemiology and psychiatric sciences·2018
Same author

Hypothalamus enlargement in mood disorders.

Acta psychiatrica Scandinavica·2018
Same author

[Attention deficit-hyperactivity disorder (ADHD) and comorbid mental disorders : ADHD-specific self-rating scales in differential diagnostics].

Der Nervenarzt·2018
Same author

Fatigue with up- vs downregulated brain arousal should not be confused.

Progress in brain research·2016

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Pharmacology

Context:

  • Placebo-controlled trials analyzed for antidepressant effects on youth.
  • Growing concerns regarding antidepressant use in pediatric populations.
  • Limited evidence for antidepressant efficacy in children and adolescents, except fluoxetine.

Purpose:

  • To evaluate the risk of suicidal ideation and acts associated with antidepressant use in pediatric populations.
  • To compare the risks of selective serotonin reuptake inhibitors (SSRIs) with other antidepressants and non-pharmacological treatments.
  • To assess the overall impact of antidepressants on suicide risk in different age groups.

Summary:

  • Reanalysis of trials indicates an increased risk of suicidal ideation and parasuicidal acts in children and adolescents treated with SSRIs or other antidepressants.

Related Experiment Videos

  • While completed suicides were not observed, the findings are significant due to weak evidence for antidepressant efficacy in this age group.
  • Antidepressants are generally considered safe for adults, aiding in suicide reduction, but a heightened risk of suicidal acts may occur in vulnerable patients during initial treatment phases.
  • No evidence suggests SSRIs pose a higher risk than other antidepressants or non-pharmacological interventions.
  • Newer antidepressants offer safety advantages in overdose compared to older tricyclic and tetracyclic antidepressants, particularly for patients with uncertain suicidality.

    • Impact:

    • Highlights the need for careful monitoring of young patients initiating antidepressant therapy.
    • Informs clinical practice regarding the risk-benefit profile of antidepressants in pediatric populations.
    • Addresses public concerns and potential negative impacts on treatment adherence and help-seeking behavior.
    • Emphasizes the importance of evidence-based prescribing and further research into pediatric psychopharmacology.